Organon & Co. · NYSE:OGN
Organon & — Shareholder Meeting (June 2023)
21 slides from Organon &'s shareholder meeting presentation, Jun 6, 2023
Slide 1: 2023 Annual Meeting of Shareholders Agenda
ORGANON & CO. Tuesday, June 6, 2023 2023 Annual Meeting of Shareholders 9:00 AM Eastern Daylight Time PART I • Opening Remarks, Call to Order and Opening of the Polls • Preliminary Procedural Remarks and Introduction Agenda PART II • Statement Regarding the Notice of Meeting, Inspector of Elections,
Slide 2: Organon Board of Directors
[Organon] Proprietary Organon Board of Directors DIRECTOR NOMINEE DIRECTOR NOMINEE DIRECTOR NOMINEE Carrie Cox Kevin Ali Robert Essner Alan Ezekowitz, Ma. Fatima de Helene Gayle, Rochelle Chairman, Organon; Chief Executive Officer, Former Chairman, M.D., Ph.D. Vera Francisco M.D., MPH Lazarus Former
Slide 3: Executive leadership team
[Organon] Proprietary Executive leadership team Kevin Ali Aaron Falcione Susanne Sandra Milligan Joseph Chief Executive Officer Chief Human Fiedler Head of Research & Morrissey Resources Officer Development Chief Commercial Head of Manufacturing Officer & Supply Vittorio Geralyn Ritter Rachel Stahle
Slide 4: 2023 Annual Meeting of Shareholders Agenda
ORGANON & CO. Tuesday, June 6, 2023 2023 Annual Meeting of Shareholders 9:00 AM Eastern Daylight Time PART I • Preliminary Procedural Remarks • Opening Remarks and Introduction of Directors and Attendees Agenda PART II • Call to Order • Statement Regarding the Notice of Meeting, Inspector of Electio
Slide 5: 2023 Organon Annual Meeting of Shareholders
2023 Organon Annual Meeting of Shareholders June 6, 2023
Slide 6: Cautionary Note Regarding Forward-Looking Statements
ORGANON & CO. 2023 Annual Meeting of Shareholders Tuesday, June 6, 2023 9:00 AM Eastern Daylight Time Disclaimer Statement – Cautionary Note Regarding Forward-Looking Statements Except for historical information, this presentation includes “forward-looking statements” within the meaning of the safe
Slide 7: Non-GAAP Information
ORGANON & CO. 2023 Annual Meeting of Shareholders Tuesday, June 6, 2023 9:00 AM Eastern Daylight Time Non-GAAP Information This presentation contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are not excluded or included in the most direc
Slide 8: 2023 Organon Annual Meeting of Shareholders
2023 Organon Annual Meeting of Shareholders June 6, 2023
Slide 9: Vision statement
Vision statement We envision a better and healthier every day for every woman. 9
Slide 10: Organon has a diverse portfolio
Organon has a diverse portfolio Our portfolio aims to empower women to make the right Women’s health choices for them with an ambition to help women Health achieve their family goals. Biosimilars were introduced with the goal of offering patients more treatment options and reducing healthcare costs
Slide 11: FY 2022 highlights
FY 2022 highlights Each Franchise Contributed to Growth $6.2B $2.1B Total Revenue Adjusted EBITDA 2 Women’s up 4%, ex-FX 1 7% growth ex-FX Health Biosimilars 17% growth ex-FX $290M $5.03 Dividends Paid to Non-GAAP Adjusted Established Shareholders Diluted EPS 2 Brands 3% growth ex-FX 1. Excluding th
Slide 12: We are building a purpose-driven company that can deliver sustainable growth
We are building a purpose-driven company that can deliver sustainable growth 8 Business development deals completed since launch. Introduced Her Promise, our comprehensive ESG strategy and goals. The number of mothers that have been 15K+ 20K+ treated with Jada, which is intended to Healthcare provid
Slide 13: First Quarter 2023 highlights
First Quarter 2023 highlights Each Franchise Contributed to Growth $1.5B $518M Total Revenue Adjusted EBITDA 2 Women’s up 3%, ex-FX 1 3% growth ex-FX Health Biosimilars 20% growth ex-FX $250M $1.08 Voluntary Debt Adjusted Diluted EPS 2 Established Repayment Brands 1% growth ex-FX 1. Excluding the im
Slide 14: 14
14
Slide 15: Questions & Answers
Questions & Answers ORGANON Here for her health
Slide 16: Thank you
Thank you ORGANON Here for her health
Slide 17: Appendix A
Appendix A ORGANON Here for her health
Slide 18: Income from continuing operations before income taxes to Adjusted EBITDA
Income from continuing operations before income taxes to Adjusted EBITDA $ mil 2022 2021 Income from continuing operations before income taxes 1,122 1,529 Depreciation 96 92 Amortization (1) 116 103 Interest expense 422 258 EBITDA 1,756 1,982 Restructuring costs 28 3 One-time costs (2) 226 231 Stock
Slide 19: Income from continuing operations before income taxes to Adjusted Net Income
Income from continuing operations before income taxes to Adjusted Net Income $ mil (except EPS) 2022 2021 Income from continuing operations before income taxes 1,122 1,529 Amortization (1) 116 103 Restructuring costs 28 3 One-time costs (2) 226 231 Stock-based compensation (3) 75 59 Total Adjustment
Slide 20: Income from operations before income taxes to Adjusted EBITDA
Income from operations before income taxes to Adjusted EBITDA Unaudited, $ in millions Q1-2023 Q1-2022 Income from operations before income taxes 235 442 Depreciation 28 25 Amortization 29 28 Interest expense 132 97 EBITDA 424 592 Restructuring costs 4 — One-time costs (1) 68 40 Stock-based compensa
Slide 21: Gross margin reconciliation
Gross margin reconciliation Three Months Ended March 31, 2023 Spin Related Stock-based Non-GAAP Unaudited, $ in millions GAAP Costs(1) Restructuring Compensation Amortization Other(1) Adjusted Revenues $ 1,538 $ 1,538 Cost of sales 580 (10) — (4) (29) (2) 535 Gross profit 958 1,003 Gross margin 62.3